Alpha Tau Medical (NASDAQ:DRTS) (NASDAQ: DRTS) is a clinical-stage company pioneering novel alpha-particle therapies for the treatment of solid tumors. Its core technology, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs radium-224 loaded sources to deliver high-energy alpha particles directly into tumor masses. This targeted approach aims to maximize cancer cell destruction while minimizing damage to surrounding healthy tissue, addressing limitations of traditional radiotherapy modalities.
The company’s primary product candidate, Alpha DaRT, is under investigation for multiple oncological indications including head and neck cancers, skin lesions and solid organ tumors. Alpha Tau Medical conducts preclinical studies and early-stage clinical trials to evaluate safety, efficacy and optimal dosing regimens. The DaRT platform is designed for integration into existing surgical and interventional procedures, offering flexibility for use alongside chemotherapy, immunotherapy and external beam radiation.
Headquartered in Caesarea, Israel, Alpha Tau Medical has established operations in the United States to support its clinical trial activities and regulatory engagements with the U.S. Food and Drug Administration. The company collaborates with leading cancer centers and academic institutions across Europe, North America and Asia, leveraging a global network of specialists to advance its pipeline and broaden patient access. Strategic partnerships also bolster manufacturing capabilities and supply chain resilience for its proprietary alpha emitters.
Founded as a spin-out from leading academic research in 2013, Alpha Tau Medical is guided by an experienced management team and board of directors. CEO Oded Magdasi brings over two decades of leadership in medical device and life sciences ventures, while Chief Medical Officer Dr. Noga Shapira oversees clinical development and regulatory strategy. Together, the leadership team is focused on driving the DaRT technology through clinical milestones toward potential commercialization.
